Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 28 29 30 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Bayer–Peking Univ: drug discovery, 201401– collab 3-year establishment of joint research center BPC/TRDD in Beijing 2014-01-08
Isarna Therapeutics–Santaris Pharma: LNA technology, 201401– license for use to discovery + develop + market TGF beta targeting immunotherapies 2014-01-08
Nestlé–Cellular Dynamics: cell research products, 201401– supply €na long-term of iCell + MyCell products to Nestlé Institute of Health Sciences 2014-01-08
Boehringer–Crystal Bioscience: therapeutic antibodies, 201401– collab discovery + developm for multiple targets 2014-01-07
Isarna Therapeutics–MIG Fonds: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Isarna Therapeutics–SEVERAL: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Isarna Therapeutics–Strüngmann Group: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Thermo Fisher–General Electric: investment, 201401–201403 acquisition $1.06b cell culture media + sera + gene modulation + magnetic beads businesses 2014-01-06
AstraZeneca–Probiodrug: CDK9 inhibitors, 201401 acquisition €na of CDK9 inhibitor program by AstraZeneca 2014-01-03
Aettis–Medigene: investment, 2014 spin-off of Aettis from Catherex with Medigene receiving 39% shareholding in Aettis 2014-01-01
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex 2014-01-01
Dinkelberg Analytics–Altmann Analytik: investment, 201401 acquisition 2014-01-01
Helmholtz–NN: mass spectrometer, 2014 supply PLANNED installation of SIMS at UFZ in Leipzig 2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon 2014-01-01
Laboratorios LETI–Curetis: Unyvero system, 201401– distribution excl in Spain + Portugal by Laboratorios LETI 2014-01-01
Padlock Therapeutics–Evotec: drug discovery services, 201401–201412 collab to deliver multiple PAD inhibitor development candidates 2014-01-01
Peqlab–VWR International: investment, 2014 acquisition of Peqlab Biotechnologie GmbH inkl Clemens GmbH by VWR 2014-01-01
Proteome Sciences–Thermo Fisher: mass spectrometer, 201401 supply installation Orbitrap Fusion MS as part of license deal w Thermo 2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Tusk Therapeutics–Droia Oncology Ventures: investment, 201809 existent majority shareholder + founding investor 2014-01-01
Biognosys–OTHER: credit, 201312 convertible loan $1m 2013-12-31
Optronik–Carl Zeiss: investment, 201312 acquisition 100% of former excl Turkish distribution partner by Carl Zeiss Meditec 2013-12-31
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
Boehringer–Circuit Therapeutics: drug target discovery, 201312– collab research €na 3y in field of psychiatric disorders 2013-12-18
Merck (DE)–CNIO: ATR kinase inhibitor, 201312– license excl rights to develop + commercialise ATR kinase inhibitors to Merck Serono 2013-12-18
Structural Genomics Consortium–Bayer: epigenetics, 201312– collab Bayer HealthCare joins SGC as new member 2013-12-18
Emergent BioSolutions–Minapharm: AGE1.CR cell line, 201312– license expansion €na broad non-excl commercial multi-product from ProBioGen 2013-12-17
Automation Partnership–Sartorius: investment, 201310–201312 acquisition €33m in cash of TAP Biosystems Group plc by Sartorius Stedim Biotech GmbH 2013-12-16
Pfizer–Siemens: companion diagnostics, 201312– collab developm + commercialisation master agreement w Siemens Healthcare Diagnostics Inc 2013-12-16
Strüngmann Group–Formycon: biosimilar, 201312– license ww excl to Lucentis biosimilar FYB201 to Santo Holding GmbH 2013-12-12
Roche–Prothena: therapeutic antibodies, 201312– collab ww co-develpm + co-promotion up to $600m + royalties ABs against Parkinson’s 2013-12-11
Covagen–SEVERAL: investment, 201312 tranched Series B CHF42m with option to obtain additional CHF14m led by new investor Gimv 2013-12-09
Biocartis–VIB: molecular diagnostics cancer test, 201312– license €na microsatellite instability (MSI) biomarkers from VIB for cancer tests 2013-12-06
Bayer–Druggability Technologies: drug delivery technology, 201312– collab multi-year to deploy Super-API platform to Bayer HealthCare molecules 2013-12-05
FN Semillas–Bayer: investment, 201312 acquisition €na by Bayer CropScience 2013-12-05
Sonic Healthcare–Ariosa Diagnostics: Harmony Prenatal Test, 201312 supply existent Sonic Healthcare offers test via TDL in the UK 2013-12-05
Sonic Healthcare–Ariosa Diagnostics: Harmony Prenatal Test, 201312– supply Sonic Healthcare will offer test via Bioscientia in Germany 2013-12-05
Euroimmun–Mecklenburg-Vorpommern (govt): grant, 201312– grant €3.15m to support total Euroimmun €14m investment to expand Dassow facility 2013-12-04
Roche–Molecular Partners: DARPins, 201312–201507 collab + license CHF55m upfront + CHF1b milestones + royalites cancer DARPin-toxin TERMINATED 7/15 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $1b 4.15% Senior Notes due 2024 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $400m 5.3% Senior Notes due 2044 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $900m 1.3% Senior Notes due 2017 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $900m 2.4% Senior Notes due 2019 to part-finance Life Technologies acquisition 2013-12-04
Pfizer–Protagen: biomarker discovery services, 201312– collab use SeroTag process to identify markers for autoimmune drug developm 2013-12-03
Sigma-Aldrich–Glantreo: LC column technology, 201312 collab developm + license Ecoprous silica manufacturing process 2013-12-03
Telormedix–SEVERAL: investment, 201312 financing round Series B extension CHF6m ($6.6m) from existing investors Aravis Venture + ProQuest Investments 2013-12-02
Paion–Capital Ventures International: investment, 201312–201402 private placement €6.17 acquisition 2.55m new shares in 2 tranches by CVI 2013-12-01
TocopheRx–Merck (DE): investment, 201312 seed financing $3.2m from MS Ventures for spin-off from Merck Serono 2013-12-01
Algeta–Bayer: investment, 201311– acquisition proposal by Bayer NOK362/share valuing Algeta equity at €2.1b 2013-11-26
Gilde Investment–SEVERAL: investment, 201311 final close of €145m Gilde Healthcare III fund 2013-11-26
R-Pharm–Paion: remimazolam, 201310– license excl €1m upfront + €3m milestones + royalties for developm + manuf + marketing in Russia + CIS 2013-11-26
R-Pharm–Paion: remimazolam, 201311– license €1m upfront + €3m milestones + royalties for developm + marketing in Turkey to TR-Pharm 2013-11-26
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax 2013-11-21
Boehringer–Galapagos: drug discovery, 201311– supply integrated drug discovery services by BioFocus to undisclosed Boehringer target 2013-11-20
Definiens–Affect: public relations, 201311 service existent by Affect Inc 2013-11-20
GAS GmbH–Imspex: investment, 201311 acquisition of 100% of G.A.S. by Imspex Diagnostics Ltd 2013-11-20
Global Bioenergies–Germany (govt): grant, 201311– BMBF grant €5.7m for Global Bioenergies GmbH within BioEconomy programme 2013-11-20
Merck (DE)–Biopharm: therapeutic protein, 201311– collab €na r+d biopharmaceutical for osteoarthritis with Merck Serono 2013-11-20
Metamark Genetics–Definiens: image analysis s/w, 201311– collab + supply multi-year agreem to use Cognition Network Technology with ProMark test 2013-11-20
CI3 Cluster–AbbVie: personalised immunotherapy, 201311 collab existent AbbVie Deutschland GmbH & Co KG is cluster partner 2013-11-19
CI3 Cluster–Bayer: personalised immunotherapy, 201311 collab existent Bayer Vital GmbH is cluster partner 2013-11-19
CI3 Cluster–Biopharm: personalised immunotherapy, 201311 collab existent PW Technologies GmbH is cluster partner 2013-11-19
CI3 Cluster–Dr Falk Pharma: personalised immunotherapy, 201311 collab existent Dr Falk Pharma GmbH is cluster partner 2013-11-19
CI3 Cluster–GenXPro: personalised immunotherapy, 201311 collab existent GenXPro GmbH is cluster partner 2013-11-19
CI3 Cluster–Infraserv Höchst: personalised immunotherapy, 201311 collab existent Infraserv GmbH & Co Hoechst KG is cluster partner 2013-11-19
CI3 Cluster–itechpartners: personalised immunotherapy, 201311 collab existent itechpartners – Dr Rainer Wessel is cluster partner 2013-11-19
CI3 Cluster–Medatixx: personalised immunotherapy, 201311 collab existent Medatixx GmbH & Co KG is cluster partner 2013-11-19
CI3 Cluster–Medesso: personalised immunotherapy, 201311 collab existent Medesso GmbH is cluster partner 2013-11-19
CI3 Cluster–Molekularpathologie Trier: personalised immunotherapy, 201311 collab existent ProteoPath GbR is cluster partner 2013-11-19
CI3 Cluster–thinXXS Microtechnology: personalised immunotherapy, 201311 collab existent thinXXS Microtechnology AG is cluster partner 2013-11-19
Scopis–High-Tech Gründerfonds: investment, 201311 financing round Series A incl returning investor HTGF 2013-11-19
Scopis–SEVERAL: investment, 201311 financing round Series A from HTGF + VC Fonds Technologie Berlin + Falk Strascheg + Fraunhofer 2013-11-19
Cambridge Bioscience–InSphero: cell culture technology, 201311– distribution excl of InSphero 3D cell culture products + services in the UK 2013-11-18
Strüngmann Group–SEVERAL: investment, 201311 Ganymed financing round Series E €45m from existing investors ATS + MIG Fond + FCPB Gany GmbH 2013-11-18
CSM Instruments–Anton Paar: investment, 201311 acquisition of CSM Instruments SA 2013-11-15
Merck (DE)–BeiGene: cancer drug, 201311– license ww + collab co-developm + commercialisation of PARP inhibitor BeiGene-290 by Merck Serono 2013-11-13
Qiagen–Maverix Biomics: bioinformatics, 201311– collab €na product integration + co-marketing of Ingenuity iReport + Maverix Analytic Platform 2013-11-13
R-Biopharm–Candor Bioscience: immunoassays, 201311– strategic alliance in the area of companion diagnostics 2013-11-13
Roche–Immatics: cancer immunotherapy, 201311– strategic r+d collab €17m upfront + research funding + >€1b milestones to develop cancer vaccines 2013-11-13
Coral BioNet–Wacker: investment, 201311– acquisition 100% of Scil Proteins Production GmbH by Wacker Biotech GmbH from BioNet Ventures GmbH 2013-11-12
MeVis–PERSON: investment, 201311 shareholding of voting rights of Carl JG Evertsz has fallen to 14.995% 2013-11-11
Novartis–Grifols: investment, 201311–201401 acquisition $1.675b of blood transfusion diagnostis unit by Grifols 2013-11-11
JnJ–Evotec: drug discovery services, 201311– collab drug target discovery for Alzheimer drugs with JnJ Innovation Centre California 2013-11-08
Auven Therapeutics–Five Prime: human antibodies, 201311– license excl €na to develop cancer ADCs to ADC Therapeutics 2013-11-05
Biocartis–SEVERAL: investment, 201311 financing round Series E €30m from existing investors 2013-11-05
Midatech–SEVERAL: investment, 201311 financing round £10m led by Ippon Capital SA with £7.6m plus existing investors 2013-11-05
Hookipa–BioMedPartners: investment, 201311 financing round Series B totalling €20m incl new + co-investor BioMedPartners 2013-11-04
Hookipa–Boehringer: investment, 201311 financing round Series B totalling €20m incl new + co-investor BIVF 2013-11-04
Hookipa–Forbion: investment, 201311 financing round Series B totalling €20m incl co-lead + returning investor Forbion Capital Partners 2013-11-04
Hookipa–SEVERAL: investment, 201311 financing round Series B €20m led by Sofinnova Partners + Forbion Capital Partners 2013-11-04
Hookipa–Sofinnova: investment, 201311 financing round Series B totalling €20m incl co-lead + returning investor Sofinnova Partners 2013-11-04
Hookipa–Takeda: investment, 201311 financing round Series B totalling €20m incl new + co-investor Takeda Ventures 2013-11-04
Merck (DE)–Kadimastem: drug discovery services, 201311– collab MOU drug screening + discovery for neurodegenerative disesases Merck Serono 2013-11-04
Strüngmann Group–4SC: drug discovery services, 201311– collab discovery + optimis small molecule anti-infectives by 4SC Discovery+Crelux for AiCuris 2013-11-04
Thermo Fisher–Univ Utrecht: mass spectrometry, 201311– collab developm applications + appointm of A Makarov as Professor 2013-11-04
AlBioTex project–Germany (govt): grant, 201311– BMBF co-funding for research project on microbial production of biopolymers for medtech + textiles 2013-11-01
DISCO project–EU (govt): grant, 201311–201710 FP7 grant €6.5m to develop bioactive compound extraction procedures 2013-11-01
m2p-labs–SEVERAL: investment, 201311 3rd financing round Fidura Private Equity Fonds + HTGF 2013-11-01
CRM Clinical Trials–Venn Life Sciences: investment, 201310 acquisition €0.6m in shares ANNOUNCED 2013-10-31
next pagenext page 1 2 3 ... 28 29 30 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top